| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514078000 | Lecithins | 49 |
| 20090005345 | Detoxification of Shellfish - The present invention relates to the detoxification of bivalves and other shellfish. More particularly, the invention relates to a feed composition and a method for detoxifying shellfish, and the use of a surface-active agent for the detoxification of bivalves and other shellfish. | 01-01-2009 |
| 20090111773 | Compositions and methods of using lamellar bodies for modifying linear biological macromolecules - Compositions comprising therapeutically effective amounts of lamellar bodies for the modification of linear macromolecules are disclosed. These lamellar compositions are useful in the treatment of conditions or diseases characterized by a preponderance of heavy mucous secretions, such as otitis media, cystic fibrosis, bronchitis, sinusitis and nasal congestion. Methods of treating these diseases and conditions by administering a therapeutically effective amount of a composition to a patient requiring such treatment are also disclosed. | 04-30-2009 |
| 20090131368 | MIXTURES OF AND METHODS OF USE FOR POLYUNSATURATED FATTY ACID-CONTAINING PHOSPHOLIPIDS AND ALKYL ETHER PHOSPHOLIPIDS SPECIES - A chemical composition of a molecular species mixture of phospholipids, purified to at least 85% purity through chromatography purification, the chemical composition contains enriched both sn-1-acyl fatty chains/sn-2-docosahexaenoic acid molecular species and sn-1-ether fatty chains/sn-2-docosahexaenoic acid molecular species, the phospholipids are selected from the group consisting of: phosphatidylcholine, phosphatidylserine and phosphatidylethanolamine. Methods using the above disclosed composition in mammals to treat various conditions. | 05-21-2009 |
| 20090176741 | MODULATION OF THE IMMUNE SYSTEM BY INOSITOL PHOSPHOLIPIDS - The invention relates to the field of immunology. More specifically, it relates to methods and compositions to suppress the immune system, among other by interference with antigen-presenting molecules and T-cell activation. Provided is a composition for the prevention or treatment of a condition wherein suppression of T cell activation is desirable, comprising as an active ingredient an inositol phospholipid or a pharmaceutically acceptable salt thereof. Said condition can be an auto-immune disease, allergic disorder or chronic inflammatory disease, for example asthma, diabetes Type I, rheumatoid arthritis (RA) or inflammatory bowel disease (IBD). Also provided is a food item or food supplement having immunomodulating properties, comprising an effective amount of an inositol phospholipid. | 07-09-2009 |
| 20090298793 | Acylgycerophospholipids for treating symptoms concomitant with cancer - The invention relates to the use of acylglycerophospholipids, in particular of hydrogenated acylglycerophospholipids and of phospholipids with a high omega-3 fatty acid content, for the production of a medicament for treating symptoms concomitant with cancer, in particular for treating tumour cachexia, cancer-related problems and pain, and for the prophylaxis of tumour growth and metastasis. | 12-03-2009 |
| 20090312287 | MULTI-CAROTENOIDS COMPOSITIONS AND METHODS - A stable nutritional supplement composition for oral administration comprising, in one form, about 71% by weight, of a tomato extract containing therein at least 2% to 10% by weight of lycopene, 0.25% to 2% by weight of phytoene, and 0.2% to 2% by weight of phytofluene, and about 29% by weight, of a suitable encapsulating matrix. A suitable encapsulating matrix is an edible oil exemplified by soya oil, pumpkin seed oil, grape-seed oil and the like. The tomato extract may additionally comprise one or more of at least one carotene selected from the group comprising .beta.-carotene, .gamma.-carotene, and .delta.-carotene, a phytosterol, a tocopheral and a phospholipid. The tomato extract may be further processed into oleoresin emulsions, or into beadlets, or into dry powders. Methods for ameliorating the effects of aging-related urinary tract malfunctions in men, comprising orally administrating on a regular basis, an effective amount of the nutritional supplement compositions disclosed herein. | 12-17-2009 |
| 20100087397 | USE OF LIPID CONJUGATES IN THE TREATMENT OF CONJUNCTIVITIS - In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to a subject with conjunctivitis. | 04-08-2010 |
| 20100137252 | Ophthalmic composition - The ophthalmic composition of the invention comprises (A) lecithin and (B) at least one refrigerant selected from the group consisting of camphor, borneol, eucalyptus oil, and bergamot oil. In the ophthalmic composition, the odor of lecithin is efficiently masked by the refrigerant. The odor of lecithin after aging is also masked by the refrigerant. Since the refrigerant is volatile, the concentration thereof in a composition tends to gradually decrease. It is surprising that the odor of lecithin after aging can nevertheless be masked. | 06-03-2010 |
| 20100144677 | METHOD FOR SCREENING AGENTS FOR THE TREATMENT OF DIABETES - A convenient screening tool and a convenient screening method for obtaining an agent for treating diabetes, a pharmaceutical composition for treating diabetes, and a process for manufacturing the pharmaceutical composition are disclosed. | 06-10-2010 |
| 20100179107 | N-ACYL-PHOSPHATIDYL-ETHANOLAMINES AND/OR MIXTURES OF N-ACYL-ETHANOLAMINES WITH PHOSPHATIDIC ACIDS OR LYSOPHOSPHATIDIC ACIDS - Pharmaceutical, cosmetic and dietetic compositions and functional foods, constituted by: A) phospholipid mixtures containing N-acyl-phosphatidyl-ethanolamines (NAPEs) and/or B) phospholipid mixtures containing N-acyl-ethanol amines (NAEs) together with phosphatidic acids (PAs) and/or lysophosphatidic acids (LPAs) with the proviso that said N-acyl-phosphatidyl-ethanolamines (NAPEs) do not include N-oleoyl-phosphatidyl-ethanolamine. New phosphobioflavonic complexes of NAPE or NAE with one or more bioflavonoids are also disclosed. | 07-15-2010 |
| 20100261676 | Use of an Endogenous Ligand for Peroxisome Proliferator Activated Receptor Alpha to Treat Liver Disorders - Compositions comprising the peroxisome proliferator-activated receptor alpha (PPARα)-ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC) are disclosed. These compositions may be used for the prophylaxis and treatment of PPARα-related liver disorders including, but not necessarily limited to, fatty liver disease, to lower lipid and triglyceride levels, and to increase high density lipoprotein levels in animals. Foods modified with 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1GPC) may be used to improve the metabolism of animals. | 10-14-2010 |
| 20100273741 | Apparatus and Methods for Adipose Tissue Detection - The present invention finds application in the field of cosmetic medicine and particularly relates to an apparatus for adipose tissue detection which comprises a first electronic circuit for generating a beam of electromagnetic waves, radiating means for orienting the beam to an adipose tissue-containing part, sensor means for detecting reflected waves, a second electronic circuit for receiving the reflected electromagnetic waves, a unit for measuring a predetermined characteristic of the reflected waves and for producing an analog signal, a third electronic circuit for converting the analog signal into a digital signal, interface means providing an interface between the third electronic circuit and a graphic processing unit. The first electronic circuit comprises means for modulating the frequency of the generated waves, which operate in a microwave range from 1 GHz to 12 GHz. | 10-28-2010 |
| 20100292186 | Pharmaceutical Composition for Treatment or Prevention of Liver Cancer - An object of the present invention is to provide an excellent liver cancer treatment agent or prevention agent. The present invention provides a pharmaceutical composition for treating or preventing liver cancer, comprising menatetrenone, which is one species of vitamin K, and a phospholipid, said phospholipid being preferably egg yolk lecithin or soybean lecithin. | 11-18-2010 |
| 20100317622 | Producing Method of Phospholipids Including Long-Chain Polyunsaturated Fatty Acids as Constituents, and Use of Such Phospholipids - The present invention provides a method of efficiently and stably producing LCPUFA-PL. Specifically, the invention provides a method for producing phospholipids that contain LCPUFA as a constituent (LCPUFA-PL), wherein lipid producing cells producing lipids that contain long-chain polyunsaturated fatty acids (LCPUFA) are used as a starting material, the method including a PL extracting step of extracting phospholipids (PL) from defatted cells obtained by extracting triglyceride (TG)-containing oil or fat from the lipid producing cells. | 12-16-2010 |
| 20110028434 | LONG-CHAIN POLYUNSATURATED FATTY ACIDS (LC-PUFA) IN MATERNAL NUTRITION DURING PREGNANCY AND LACTATION - The present invention relates in general to maternal food compositions. In particular, the present invention relates to maternal food compositions comprising LC-PUFA and their uses. Embodiments of the present invention relate to maternal food compositions comprising a source of lipids, wherein the source of lipids includes at least one LC-PUFA in the form selected from the group consisting of phospholipids (PL), phosphotidylcholine (PC), phosphatidylethanolamine (PE), N-Acylphosphatidylethanolamine (NAPE), phosphatidylinositol (Pl), phosphatidylserine (PS) or their lyso derivatives and their uses in brain development and eye development of neonates. | 02-03-2011 |
| 20110034415 | WALNUT EXTRACTS FOR NUTRACEUTICAL APPLICATIONS - The invention describes to walnut oil extracts that have increased amounts of enriched in phospholipids, especially phosphatidylethanolamine (PE), phosphatidylcholine (PC), and phosphatidylinositol (PI) relative to walnut oil found in naturally occurring walnuts. It has been found that there are synergistic therapeutic effects when PE/PC and/or PI are combined. | 02-10-2011 |
| 20110098249 | COMPOSITIONS AND METHODS OF TREATMENT FOR ALLEVIATING PREMENSTRUAL SYNDROME SYMPTOMS - The present invention discloses pharmaceutical/nutritional compositions for alleviating symptoms associated with premenstrual syndrome (PMS) and methods of treatment for PMS using such pharmaceutical/nutritional composition including: at least 2% (w/w) phosphatidyl-L-serine, or salts thereof, out of a total composition, as an effective ingredient, wherein: the phosphatidyl-L-serine has a structural fatty-acid chain derived from at least one raw material lecithin. Preferably, the phosphatidyl-L-serine is produced by enzymatic reaction of at least one raw material lecithin with phospholipase-D; at least one raw material lecithin is selected from the group consisting of: a vegetal lecithin and a non-vegetal lecithin; and the phospholipase-D is selected from the group consisting of: vegetal phospholipase-D, bacterial-originated enzyme phospholipase-D, and a combination of vegetal phospholipase-D and bacterial-originated enzyme phospholipase-D. Preferably, the structural fatty-acid chain is a saturated, hydrogenated fatty-acid chain. Preferably, the phosphatidyl-L-serine is derived from a dairy lecithin. | 04-28-2011 |
| 20110105433 | LECITHIN AND LC-PUFA - The present invention relates generally to the prevention/and or stopping of the generation of off-flavours in food products. In particular is the present invention directed to the formulation of lipid raw material mixes and food products containing long chain polyunsaturated fatty acids, and to compositions and processes for stabilizing such products against the formation of off-flavours, such as fishy off-odours. One embodiment of the present invention is a composition comprising an LC-PUFA containing oil and lecithin, wherein weight ratio of lecithin to LC-PUFA is at least about 25:75. | 05-05-2011 |
| 20110160161 | CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONS - The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition. | 06-30-2011 |
| 20110212922 | PROCESSES FOR THE PREPARATION OF PHOSPHATIDE SALTS - The present invention discloses processes a process for the preparation of phosphatide-salt complexes, the process including the steps of: using at least one raw material lecithin as a substrate; and enzymatically processing at least one raw material lecithin with phospholipase-D, racemic or enantiomerically-pure serine, and/or amine in an aqueous carboxylate-salt-complex solution, wherein the step of processing is performed in a single-phase reaction environment, to produce phosphatide-salt complexes having a structural fatty-acid chain derived from at least one raw material lecithin. Preferably, the step of processing is performed at a pH in the range of about 4.5-8.0 at a temperature in the range of about 25-60° C. Preferably, the aqueous carboxylate-salt-complex solution is formed from an aqueous solution of a carboxylic acid with a chain length of C2-C8 and a salt in an approximately 1:2 (weight per weight) acid-to-salt ratio. | 09-01-2011 |
| 20110251158 | FULLERENE THERAPIES FOR INFLAMMATION AND INHIBITION OF BUILD-UP OF ARTERIAL PLAQUE - Described herein are methods for treating inflammatory disorders or for inhibiting the build-up of arterial plaque. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene. | 10-13-2011 |
| 20110294757 | POLAR LIPID MIXTURES, THEIR PREPARATION AND USES - Disclosed herein are polar lipid mixtures, comprising glycerophospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidyl-inositol (PI), and sphingolipids such as sphyngomyelin (SM). Most importantly, the ratio of phospholipids in said mixture is comparable to that of HMF, and is represented by SM>PC>PE>PS>PI or SM=PC>PE>PS>PI. Processes for the preparation of said mixtures and uses thereof are also described herein. | 12-01-2011 |
| 20110306577 | TOPICAL SKIN CREAM COMPRISING PHOSPHATIDYLCHOLINE DHA AND L-TYROSINE - The present invention relates to compositions and methods of treating skin. In particular, the present invention relates to the topical application to the skin of compositions for the prevention and/or treatment of damage to skin. | 12-15-2011 |
| 20120028921 | METHODS AND COMPOSITIONS USING OXIDIZED PHOSPHOLIPIDS - The instant invention provides compositions, e.g., compositions comprising oxidized phospholipids, for the treatment of diseases, disorders and conditions, e.g., cute lung injury syndromes, sepsis, vascular leakage, edema, acute respiratory distress syndrome (ARDS) or acute inflammation. | 02-02-2012 |
| 20120028922 | NATURAL MARINE SOURCE PHOSPHOLIPIDS COMPRISING POLYUNSATURATED FATTY ACIDS AND THEIR APPLICATIONS - A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid. | 02-02-2012 |
| 20120040934 | OMEGA-3 ENRICHED FISH OIL-IN-WATER PARENTERAL NUTRITION EMULSIONS - An emulsion is provided including: an oil component and a water component, the oil component including: fish oil triglycerides in an amount of about 60% to about 90% based on the weight of the oil component; wherein the fish oil triglycerides include omega-3 fatty acids, expressed as triglycerides, in an amount of at least 60%, based on the total weight of the fatty acids of the fish oil triglycerides; wherein the fish oil triglycerides include a total amount of EPA and DHA, expressed as triglycerides, of at least 45%, based on the total weight of the fatty acids of the fish oil triglycerides; and, at least one medium-chain triglyceride, wherein a total amount of the at least one medium-chain triglyceride is from about 10% to about 40% based on the weight of the oil component. | 02-16-2012 |
| 20120149664 | Transdermal Composition of Phosphatidylcholine and Method for Producing Same - Disclosed is a transdermal composition, which uses high-purity phosphatidylcholine that is most susceptible to oxidation and the like, and which exhibits high stability and high migration into the skin. Specifically, a transdermal composition having good stability and migration into the skin is able to be obtained by preparing a transdermal composition (a colloidal dispersion liquid of phosphatidylcholine) that contains high-purity phosphatidylcholine, carnitine, a polyhydric alcohol and water. Since the transdermal composition does not contain an oleaginous base (an oil component), the transdermal composition has skin compatibility and is thus useful as a therapeutic agent or a cosmetic preparation. In addition, phosphatidylcholine and carnitine have an effect of achieving good migration into the skin and are capable of promoting systemic or local lipid metabolism in subcutaneous adipose tissues. Consequently, the transdermal composition is able to provide a transdermal preparation that is capable of promoting lipolysis in subcutaneous adipose tissues. | 06-14-2012 |
| 20120283218 | MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES - Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A | 11-08-2012 |
| 20120302525 | SYNTHETIC BILE ACID COMPOSITIONS AND METHODS - Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties. | 11-29-2012 |
| 20130040913 | OMEGA 3 FATTY ACIDFOR USE AS A PRESCRIPTION MEDICAL FOOD AND OMEGA 3 FATTY ACID DIAGNIOSTIC ASSAY FOR THE DIETARY MANAGEMENT OF CARDIOVASCULAR PATIENTS WITH CARDIOVASCULAR DISEASE (CVD) WHO ARE DEFICIENT IN BLOOD EPA AND DHA LEVELS - The present invention provides a kit for the dietary management of cardiovascular patients with cardiovascular disease who are deficient in blood Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) levels, the kit including a diagnostic assay for determining blood levels of EPA, DHA and Docosapentaenoic acid (DPA) and a pharmaceutical grade prescription medical food omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of EPA, DPA and DHA in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA are about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition. The kit may further contain instructions for use of its components. | 02-14-2013 |
| 20130096087 | INFANT NUTRITION FOR IMPROVING FATTY ACID COMPOSITION OF BRAIN MEMBRANES - The present invention relates to infant nutrition, in particular to infant nutrition comprising special lipid globules for improvement of the fatty acid composition in brain membranes. | 04-18-2013 |
| 20130116212 | OIL-BASED GEL-LIKE COMPOSITION - There is provided a gel-forming agent which is easily prepared and has all of high safety in the living body and the environment, good gel-forming capability, excellent use feeling, and good handleability. | 05-09-2013 |
| 20130150328 | Cosmetic Composition - To provide a transparent to translucent cosmetic composition which is highly stable, and can impart excellent actual feelings of effectiveness in use, such as a feeling of skin penetration, a feeling of non-stickiness, and a skin-softening effect after application thereof to the skin. A transparent to translucent cosmetic composition comprising: (a) a hydrogenated phospholipid, (b) one or more selected from among branched higher fatty acids and higher alcohols, and (c) a polyalcohol that acts as a good solvent and/or a poor solvent for component (a). Preferably, component (b) is isostearic acid and/or isostearyl alcohol. Preferably, the ratio of component (a)/component (b) is from 1/0.01 to 1/0.4 (by mass). | 06-13-2013 |
| 20130157978 | PREPARATION FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISORDERS - The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions:
| 06-20-2013 |
| 20130261084 | METHOD OF IMPROVING RESPONSE TO CHEMOTHERAPY BY ADMINISTERING A PHOSPHOLIPID TOGETHER WITH CHEMOTHERAPEUTIC AGENTS, AND FORMULATIONS THEREFOR - Methods and formulations for improving efficacy of chemotherapeutic treatment. The formulation includes at least one chemotherapeutic agent and at least one phospholipid or a material comprising the same. The phospholipid facilitates entry of the at least one chemotherapeutic agent into cells of an afflicted individual. A sufficient dosage of a blood-thinning agent is optionally included to mitigate risk of developing blood clots attributable to administration of the chemotherapeutic agent(s). The chemotherapeutic agent(s) and the phospholipid(s), or the material containing the phospholipid(s), are administered in any order but in sufficient time proximity to one another such that the effect of the phospholipid(s) of facilitating entry of the chemotherapeutic agent(s) into the cells at least partially overlaps with the therapeutic effect of the chemotherapeutic agent(s). | 10-03-2013 |
| 20130261085 | METHOD OF IMPROVING RESPONSE TO CHEMOTHERAPY BY ADMINISTERING A PHOSPHOLIPID TOGETHER WITH CHEMOTHERAPEUTIC AGENTS, AND FORMULATIONS THEREFOR - Methods and formulations for improving efficacy of chemotherapeutic treatment. The formulation includes at least one chemotherapeutic agent and at least one phospholipid or a material comprising the same. The phospholipid facilitates entry of the at least one chemotherapeutic agent into cells of an afflicted individual. A sufficient dosage of a blood-thinning agent is optionally included to mitigate risk of developing blood clots attributable to administration of the chemotherapeutic agent(s). The chemotherapeutic agent(s) and the phospholipid(s), or the material containing the phospholipid(s), are administered in any order but in sufficient time proximity to one another such that the effect of the phospholipid(s) of facilitating entry of the chemotherapeutic agent(s) into the cells at least partially overlaps with the therapeutic effect of the chemotherapeutic agent(s). | 10-03-2013 |
| 20130316980 | Hypotonic Aqueous Composition with Reduced Chloride Content, With or Without Phospholipids - An aqueous composition for application in a method for surgical or therapeutic treatment of the human or animal body or in a diagnostic procedure which is practiced on the human or animal body, the composition comprising osmotically active particles and containing less than 70 μl | 11-28-2013 |
| 20140005144 | NOVEL LEUKOTRIENE RECEPTOR ANTAGONIST | 01-02-2014 |
| 20140051663 | GLYCEROPHOSPHOLIPIDS FOR THE IMPROVEMENT OF COGNITIVE FUNCTIONS - The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations. | 02-20-2014 |
| 20140107072 | New Method For Making Krill Meal - A new method for krill meal production has been developed using a two step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum. In the second stage the krill without phospholipids are cooked. Following this, residual fat and astaxanthin are removed from the krill using mechanical separation methods. A novel krill meal product with superior nutritional and technical properties is prepared. | 04-17-2014 |
| 20140155354 | PROCESSES FOR THE PREPARATION OF PHOSPHOLIPID-ENRICHED DAIRY PRODUCTS AS NEUTRACEUTICALS FOR THE FORMULATION OF FUNCTIONAL FOODS, AND NEUTRACEUTICAL AND/OR PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention discloses processes for the preparation of phospholipid-enriched dairy products as nutraceuticals for the formulation of functional foods, and nutraceutical and/or pharmaceutical compositions thereof, the processes include the steps of: combining a non-dairy-based PL-containing material with an oil component and water to form a paste; removing an excess amount of the water from the paste to form a PL-oil solution; and mixing the PL-oil solution with a dairy component, thereby obtaining a PL-enriched dairy product. Preferably, the PL-containing material includes at least one material selected from the group consisting of: a vegetal-derived lecithin, a non-vegetal-derived lecithin, a de-oiled lecithin, a native lecithin-oil solution, and an enzymatically-processed lecithin. Preferably, the PL-oil solution has a weight-to-weight (w-w) concentration of at least about 0.01% of a residual amount of the water to the PL-containing material. | 06-05-2014 |
| 20140171391 | METHOD FOR TREATING SEPSIS IN PATIENTS WITH ALBUMIN, CHOLESTEROL AND HDL LEVELS ABOVE MINIMUM THRESHOLDS - The invention relates to a method for treating sepsis in subjects who exhibit serum albumin levels, and one of total cholesterol or HDL levels, above minimum threshold values. The method involves intravenous administration of an emulsion, which contains a phospholipid, a neutral lipid, and a cholate salt. | 06-19-2014 |
| 20140274957 | METHODS AND COMPOSITIONS FOR CORRECTION OF ORGAN DYSFUNCTION - The present invention includes compositions and methods for treating certain conditions, the composition comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is used to treat at least one of autonomic dysfunctions or vascular diseases. | 09-18-2014 |
| 20150011507 | COMPOSITIONS COMPRISING LECITHIN OILS AND NSAIDS FOR PROTECTING THE GASTROINTESTINAL TRACT AND PROVIDING ENHANCED THERAPEUTIC ACTIVITY - A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration. | 01-08-2015 |
| 20150065462 | CONJUGATES OF A PHOSPHOLIPID AND A DRUG FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - Conjugates of drugs suitable for use in the treatment of inflammatory bowel disease and phospholipids, and their use in the treatment of inflammatory bowel disease, are disclosed. The disclosed conjugates serve as targeted prodrugs which are suitable for oral administration, and which are capable of releasing the drug selectively at the diseased tissue upon activation by PLA | 03-05-2015 |
| 20150306117 | INFANT NUTRITION FOR IMPROVING FATTY ACID COMPOSITION OF BRAIN MEMBRANES - The present invention relates to infant nutrition, in particular to infant nutrition comprising special lipid globules for improvement of the fatty acid composition in brain membranes. | 10-29-2015 |
| 20160015820 | GLYCEROPHOSPHOLIPIDS FOR THE IMPROVEMENT OF COGNITIVE FUNCTIONS - The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations. | 01-21-2016 |
| 20160058780 | COMPOSITION FOR LIPOLYSIS, CONTAINING PHOSPHATIDYLCHOLINE, AND PREPARATION METHOD THEREFOR - A composition for inducing lipolysis includes phosphatidylcholine and a preparation method therefor. More particularly, the composition for inducing lipolysis may include 2-12% (w/v) of phosphatidylcholine, 5-12% (w/v) of an oily solvent, and a balance of water; and a preparation method thereof. The composition may include phosphatidylcholine, an oily solvent, and water to induce lipolysis without causing such adverse side effects as edema, erythema, tissue necrosis, and inflammation. | 03-03-2016 |
| 20160199269 | METHOD FOR PREPARING NANOEMULSION | 07-14-2016 |
